Clinical Studies

“Arthramid® Vet is used everyday and around the world for the treatment of lameness in horses. Multiple published studies from high profile institutions, and treating thousands of equine patients across all equestrian disciplines, show that Arthramid®Vet is a safe and effective treatment for osteoarthritis and joint lameness in animals. Explore this page for more information and to access findings from studies of Arthramid® Vet 2.5% PAAG”


Innovative Medical Solutions

Arthramid Vet White Paper

Get your copy of our 24 page white paper covering Treatment of Joint Lameness, Pathophysiology, Manufacturing, Mechanism of Action, Clinical Safety and Putting it into Practice.

Send Me The White Paper

First Name:
Last Name:
Your Email:
Practice Name:

Janssen, I., Koene, M., and Lischer, C. (2012). Intraarticular application of polyacrylamide hydrogel as a treatment of osteoarthritis in the distal interphalangeal joint: Case series with 12 horses

Tnibar et al (2014). Evaluation of a polyacrylamide hydrogel in the treatment of induced osteoarthritis in a goat model: a randomized controlled pilot study

Tnibar et al (2015). An international multi-centre prospective study on the efficacy of an intraarticular polyacrylamide hydrogel in horses with osteoarthritis: a 24 months follow-up

Christensen, L., Illigen, K.E., Hansen, M., Sarvaa, R., and Conogham, P.G. (2016). Synovial incorporation of polyacrylamide hydrogel after injection into normal and osteoarthritic animal joints

Bathe, A.P., Read, R.M., and Briggs, C. (2016). Intra-articular polyacrylamide hydrogel for the treatment of 20 horses with non-responsive osteoarthritis of the interphalangeal joints: a prospective study

Tnibar,A., Persson, A.B., and Jensen, H.E. (2017). Mechanisms of Action of an Intraarticular 2.5% Polyacrylamide Hydrogel (Arthramid Vet) in a Goat Model of Osteoarthritis: Preliminary Observations

Henrikson, M., Overgaard, A., and Bliddal, H. (2017). Initial Estimates of Efficacy of Intra-Articular 2.5% Polyacrylamide Hydrogel for the Treatment of Knee Osteoarthritis: An Observational Proof-of-Concept Study

de Clifford, L.D., Lowe, J.N., McKellar, C.D., Bolwell, C., and David, F. (2019). Use of a 2.5% Cross-Linked Polyacrylamide Hydrogel in the Management of Joint Lameness in a Population of Flat Racing Thoroughbreds: A Pilot Study

Treatment of Joint Lameness & Osteoarthritis (OA) In Horses

Osteoarthritis (OA) is considered one of the most important musculoskeletal disorders in both humans and horses. 1, 2 Clinically, it is associated with lameness and dysfunction of the affected joint and approximately 60% of all equine lameness is due to OA. 3, 4It is characterised by breakdown and loss of joint cartilage, bony overgrowths (osteophytosis- seen on radiographs), (read more)

  • Novel treatment for lameness.
  • Treats underlying disease process.
  • Positive effect on articular components.
  • Reduces mechanoreceptor activation.
  • Long lasting tissue compatibility.

Clinical Safety of Arthramid Vet 2.5% PAAG Hydrogel

Both in vitro and in vivo studies have taken place, designed to generate data on the safety of Arthramid Vet and to support regulatory submissions for market authorisation. Most current OA treatments are focused on reducing symptoms, and there are few effective treatments that address the underlying cause of the disease. (read more)

  • Multiple Safety Studies.
  • Neuro-innocuous.
  • No adverse side effects.
  • Widespread use in human medicine.
  • Safe for competiton.

Arthramid Vet 2.5% PAAG- Mechanism Of Action 

Arthritis describes inflammation of a joint and can happen after either a single or repetitive episodes of trauma. 31 The term incorporates synovitis, capsulitis, sprain, intra-articular fractures, meniscal tears, and osteoarthritis or OA. These pathological conditions are ‘a group of overlapping distinct diseases which may have different causes, but with similar biologic, anatomical, and clinical outcomes.’ (read more)

  • Integrates into joint capsule.
  • Restoring function to the joint.
  • Increasing visco-elastic.
  • Reduces pain & synovitis.
  • Stable & non-absorbable.

Pivotal Efficacy Study- Randomised, Double Blinded Positive Control Study

Introduction: Intra-articular administration of a 2.5% polyacrylamide hydrogel (PAAG- Arthramid Vet) is shown to reduce or abolish lameness in distal interphalangeal (coffin) and metacarpo/ metatarso- phalangeal (fetlock) joints in horses undertaking equestrian disciplines. To date, there have been no studies evaluating the effect of positive control treatments in racehorses compared to 2.5% PAAG.

Objectives: To investigate the efficacy of a 2.5% PAAG (Arthramid Vet) in the management of inter-carpal joint lameness in racing Thoroughbreds.

Study design: Prospective double-blinded positive-control study.

(read more)

Comments From Clinical Practice

Dr Kim McKellar, Australia
“I have been using Arthramid Vet for years now treating TB’s,SB’s and equestrian horses. It’s simply the best treatmetn we have for OA”  (read full)

Dr Marc Koene, Germany

“I was one of the first vets to use Arthramid worldwide and it has been a major game-changer in the way we treat OA in our patients” (read full)

Get In Touch

Contact Us

First Name:
Last Name:
Your Email:
Practice Name:

Phone +64 (09) 8013 253

Interested in talking to us and learning more?

Arthramid Vet Australia

Registered in Australia to: IMS Vet Pty Limited, 1953 Grampian's Road, Fyans Creek, Victoria 3381. Registered pursuant to the APVMA Number 86728/0320. See for registration conditions.

Available only from your veterinarian. Ask your vet to contact us today.

Address for Service:
IMSVet, PO Box 1083, Cambridge 3450, New Zealand
Phone +61 (0408) 899 940